�ICU���2020.1.28
�� �� ��
INTRODUCTION
>vitamin D0+&,?;��879:1��<D2@D73-%6=;"�'51��4�����-��-��
;����0! /12vitaminD2.D3vitamin D2<ergocalciferol= ����
vitamin D3<cholecalciferol= ����
#vitamin D31�(��vitamin D�2� )4*&$
8vitamin D.��9
INTRODUCTION
��)���.��)"225-hydroxy vitamin D625OHD7-��%3�
��*�.��)�� )"21,25-dihydroxy vitamin D(1,25OH₂D)/*��%32
0*5+.����1����#�(vitamin D receptor(VDR)-�&���)�!,�$4'2
INTRODUCTION
[vitamin DJ�>\9CaFPJ�5J4,: 7 96�J�1.�:HGF;BAN?)OQA�>��IL7
;?C<J3�*+EK�&M�(-0J�1��HGJ�>=��@QD;P8
Y 'INP2��J2��J�Y��"J��J�Y�(-0J �/%��$Y/TZWRSUXVJ���$Y��#!�$
INTRODUCTION
H��5:<2��6���6��in vitro36')<*7'� �6ECF��?�*1�&37'1,25OH₂D,�� B@DA@GIIL-1β'IL-2'IL-6'IL-17'TNF-α'IFN-γJ6��?%�/1(
H����6��
���&37'1,25OH₂D,ARDS5+*2��6#"5$><'IL-86��?��/1(81'vitamin D?��5!�0<-43' �5��0<:;9:;��6#",��.=1(
Nat Rev Endocrinol. 2011;7(6):337-345.
Steroids. 2011;76(12):1305-1309.
INTRODUCTION
D�����.�/����vitamin D/$������.�",��3�!���-��(*2%
D�7E?46:C=.����
vitamin D/$II������.7E?46:C=��'10����-#�)2%
D� ����
vitamin D/$��A@;>+&25<B89C.��3� )2%
PLoS One. 2014;9(1):e86755.
Am J Physiol Lung Cell Mol Physiol. 2005;289(4):L617-626.
Science. 2006;311(5768):1770-1773.
INTRODUCTION
•����%�)�40/50."vitamin D ���*�ICU$��+)�#��#��(��"&#��
• Institute of Medicine%��$),'�
N Engl J Med. 1998;338(12):777-783.
�
���
��
�&�-�!�vitamin D% �$ �!�
INTRODUCTION
JC 2014/12/16 �����!� ����
� ������vitamin D�����������
INTRODUCTION
JC 2014/12/16 ����')&($%��
vitamin D��������"��� #�30�90�365�!����������� �����
INTRODUCTION
^�4*IICUK�9�L�2K�EH:vitamin D_calcitriol`T��EFJCS:��(%)TOGVZ\XY]L+'@��E:Placebo1K!M �&@��K��EF;
Am J Respir Crit Care Med. 2014;190(5):533-541.
7�:=AG?L0�,3�-/?P:8*�2K>BQvitamin D5L�)�O.DRH=Q;
^�4*IICUK�9�L�2K40� �Lvitamin DT��EF JCS:25OHD#�@��12ng/ml��E:VZ\XY]L��O6NPRF;$*�WU[VU]I<QIL-1,IL-6L+'O"�EH=F;
Crit Care Med. 2015;43(9):1928-1937.
INTRODUCTION
N���)!�DICU�%Cvitamin D50���J��=?A;I525OHD �J���*B:��<>51�/D"$CG0,=@7?6
J Clin Transl Endocrinol. 2016;4:59-65.
N( Cvitamin D 20���J��=?A;I5(�DARDSDMLK9473.�2(�D&'#�FD���8HE&'#+-���J��<>?6
Thorax. 2015;70(7):617-624.
INTRODUCTION
�����vitamin D!��� �����!��� ���$
vitamin D�������������� ��$" ������ARDS���#
INTRODUCTION
ICU����#"��� �����vitamin D ����$���� ��$�!�� ���RCT $��
Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial.
JAMA 2014; 312: 1520-30
INTRODUCTION8��9
Y��Z
KUMPSIMedical University of Graz (���,)
Y%&OLJTZ
<7"�!F�=7�2#��/7'�$*�-5
Y�4Z
2010�5�[2012�3�
Y�.Z
ICUB��>G�)C:?718���@48�4��C �;+0EH725OHDY20 ng/mlC�)
YRTNQ�Z
vitamin D��(APlacebo��(B1X1@F�=
VICUDcardio surgical7neurological7medical7mixed surgical 62C513W
INTRODUCTION���
��ICU JC 2014/12/16� ���
�3000 IU/��
INTRODUCTION,��-
Primary Endpoint:
Secondary Endpoints: 7ICU��'7�)/0���(day28 and 6 month)
7!�25OHD≧30ng/ml0��(day7)
7vitamin D($*�(Ca+P+25OHD+1,25OH₂D+PTH+��Ca9
75236848(CRP+PCT)
7 ��0��(!��� �#%,NT-proBNP)
7��"��'
� &�.10)��
492��Placebo��vitamin D� ����"���#��� 475�!*.(%�������������6��!+'-.&),��$#��
INTRODUCTIONC�68#D
ICU��"Q<!RA�:.A�+�A24A�9�3A�ON
Charlson��-�� ASAP�scoreATISS-28 X,EK�6>.�Q=��5?PVRTMYNOI
�6Q�@R65$ �L��G1/3L7(��AJSK0�
]Charlson��-�� `��-�HMP\[ZG�V�KUWA�;)FU10�?Q%�*X�'B
]TISS-28`NsQ&/���X1J\[ZB78)()B^Simplified Therapeutic Intervention Scoring System_
INTRODUCTION�� ���
� �3/4����ICU��������� �
�����ICU�������� �1/4��
INTRODUCTION ��
Primary Endpoint�����������������������
INTRODUCTION����
��� ��#���!�"$&�����
Secondary Endpoints��%28��6�� ��!vitamin D������"$&������!�����
INTRODUCTION���
vitamin D��������������������25OHD≦12ng/ml�������42%��
INTRODUCTION����
/���,7��)#'25OHD��(vitamin D�# &� �28��)#&30ng/ml.��!'(���#�"!�
/)!�vitamin D�&$+%� ���(�*,-%�"!�
INTRODUCTION� �
Subgroup�������vitamin D�����������������
INTRODUCTION1 �2
.subgroup%�C/+�Cvitamin D���#C���B54=D�� 7'GHJ;0
,+�(Cvitamin D$���D�*��K��8:A6<;0
-6L�)C���Dvitamin D��">7%E@��9=4;7/!&�BPlacebo"?C�� D'GHJA6<;0
F?GI?…vitamin D��C3IICU��#B�9=/
INTRODUCTION3# 4
Qvitamin DEKN�L8D���,G+ILO>1� !E7;N�-*�G�B5NC#6LO?2
Q0�vitamin D���$E7;N1���F��G15:HBsubgroup(�B5M1<LDN�)P'=NC#6LO?2
Q���GD8@?910�-vitamin D&���G1�/�.F�"J���F��EAD9N%�95NC#6LO?2
INTRODUCTION
vitamin D+���C���L!�>J<KHC%�9H5ARDSF��C4RPO�'B8;J5���Cvitamin D+
���C 2L.�>J?E5
GI-�A$��)�/3:�,@&7HK?6
National Heart, Lung, and Blood Institute(MQRN#�(*� "�)9H01��L�;5
Prevention and Early Treatment of Acute Lung Injury(PETAL) NetworkBGI��C "D��=K?6
INTRODUCTION
w��f34q>V*#hcix
Lvitamin Df,�gF7d!9eWUa�=1bTnRX`?�elnEkXe$�bZoS
PK/Gvitamin Df?�0.gARDSk-�q�H]R<�1rsutvq$�\_o�; YToS
Q5�2<�CJXmj/./GR� RICU!9eW[o<�1�)YA\paUoS
MPETAL networkfjcICU����f%(Xm��bZRBj]k^USN!9f�IY�@+X`R�6�e�;bTnRD/��)jKUS
O vitamin Dg�bR"�Y�&bR� bTnRCJ8)Y:�1bTo��R<�1e'�^o�; YKUS
Vitamin D to Improve Outcomes by Leveraging Early Treatment / VIOLET 0 trial
�ARDS' &��.-,���vitamin D����$��!���%vitamin D �&90��%�)(*�"%
������+����*�#�
METHODS
F��G
$ 44�'9��'�!"F!"A?>DG
��1.����:�2.�+���*.#� (-
F�,G
2017�4�H2018�7�F�)G
ICU��0��3<6/;.Inclusion/Exclusion Criteria=�54�&
FCD@BG
vitamin D��%7Placebo��%81E1�:�2
METHODS
Inclusion Criteria!� 18���� ICU������� ARDS������������1������ vitamin D� �
METHODS
>Inclusion Criteria?# 18���$ ICU64� +�% ARDS(8)5��4=<;�:10����" vitamin D4��
�� &��&�� &�� 324�'3��*7ICU6� .8,1+�-9/����+�!
METHODS
QInclusion CriteriaR7 18$��8 ICUCB�;��9 ARDSF%�BNMK��I1?����6 vitamin DB#�
� ;/�<H:SOFAMLJ;2(��B����1;�3:5'O52P=@EMAP<65mmHg
�� ��A@�*<HG:>D@B"!.�&
+��4Oinfiltrates:consolidation:cavitationP0��4O�:,:-):WBC>12000P
METHODS
9Inclusion Criteria:� 18���� ICU-+��%�� ARDS!.",��+642�11(����� vitamin D+��
�;�1�'& )#$(��*��&'��,vitamin D��+4268573%�0/
��25OHD%20ng/ml��+��% �
METHODS
pExclusion CriteriaqkICO�^`VNkICU�O*�QT12$I��W.�-�UPVNk9�M_NY98U%?OUPVN
krCasq10.2m/dlnrbdj�Cas>5.2m/dlok1���LM_NYF WB#�>:5XchelgOM_k/�;"+3X�1[SY�'
k48$I&,X(�OCE[`_k�����ZX���X�0UVN
k��
k��a )G�D]HKXS\���aA4QTN_ <b ilfjU���aA4R_@� <c 24$I��X���J=OCE[`_ <d !�6972 /��U���aA4QTN_ <
METHODS ������
METHODS +.)'0-
ICU����"�����#��!���ARDS ��,(%������������vitamin D���(%,0*
/&$���
METHODS (+&$-*
vitamin D���%")-',#����������12����vitamin D���Placebo���
���1.1������! �
METHODS 463275
����/�%��2����)54��*vitamin D1��!0"+��$. �� '*�+���/*��1�,��*
vitamin D*��+&(" Placebo�-��)�#
METHODS .5+'74
�������%50+&2-#7)6*1���� 8LC/MS/MS9"����/7(2$6
Ca���25OHD��"���!�
� vitamin D���Primary Endpoint ��
vitamin D�� (%37,6&���Secondary Endpoints ��
METHODS
KVitamin D3��2-'.L• 1���4vitamin D��3;9EH@G:0*.% �#�$3�����%5+4��;<=A)FDA 3Point of care testIFast Pack System®J7�,+&
• 2���/4��9FB?:DA8H<G>C!"���ILiquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS)J7�'.��1Vitamin D%Ca��7��*+&
I� )�65/�((6J
METHODS
�Primary Endpoint������90� ��������������������
METHODS
�Secondary Endpoints�������� �
������ �
������ �
METHODS
ASecondary EndpointsB)"��;<>=?
*���;<>=?
+���;<>=?
90��83� .2-0�!6,@�(36�(�'@�6���%7 10��,/6���'
@90��5� .,#�5&(.2-9�!6��
@28��83,��:$�.2-4-�'@90��835��.0�!6,��836�'
METHODS
ISecondary EndpointsJ1)�$ABDCE
2 �$ABDCE
3��$ABDCE
7�%>9<4FARDS<#":,"�F( ��<,"�<�
3�%>9<4F+�25OHD��F+�IL-6��
a.������→P/F4FiO₂GSpO₂H4PEEPb.��'.�→1�<�0Cr�4RRTc.�+&<��→1�<��*�0�!-
Berlin�/
���6@8�<300�=3�%;25OHD��4IL-6��?��785
METHODS
WSecondary EndpointsX8&��NORPT
9���NORPT
:��NORPT
U14� HCF7Ca'�
90� HCFU%$!U,�3.F6�
vitamin DF���G2/2" <HA����?KA��F300�G;25OHD� >SVQE1@B=JD�LKJ3��FCa� I��@A<
-4�E#0(M�;90� F5*+�C)�@A<
METHODS
BStatistic AnalysisC?���05%��1�(4/��*#!��'3#Placebo�.20%#vitamin D�.15%1���.%4/��*,$
?����)54� 180A2�1vitamin D��-/��*,$
?α8<@60.05#��687.4A/��+4/#9>;=97:2� 3000��"/�&35,$
METHODS
<Statistic Analysis=9��(*Data and Safety Monitoring Board:DSMB;&! ��.���3���!1*���.��.*2-��8��)0'%,#%8��)5"
9����+3 .� �&�765":750�!1500�!$4/2250�.������;
METHODS156/-
�,-��-�"/��-�*�5�'-BMI-�*�5Vitamin D��-<?;=:>�525OHD��@LS/MS/MSA-<?;=:>�5$�#-ARDS5(�@��/+��A-SOFA score-Lung Injury Prediction Score(LIPS)-!� ��5�'�-!� ��5ARDS5��-ICU���� �4)03subgroup&�7%982.
RESULTS)+,'*,(
��!���� � ����&��$���"
�� ���
-�����&%��"1360�#������.
RESULTS�������15924��������� 13300�� �
2614��vitamin D���������
1360��vitamin D������������
RESULTS�������
1360��vitamin D�Placebo��������
690� vitamin D�2� �����
668� Placebo�
RESULTS"$% #%!
Placebo���528��Primary Endpoint�
����
vitamin D���531��Primary Endpoint�
����
LC/MS/MS�����2��������vitamin D��
vitamin D�538� Placebo�540�
7��� ��� 12��� ���
RESULTS ���
���55 ���$$�#����� !���$$�����"���������"%����
RESULTS ��!�
ARDS1*0��/$853� -(+% �3�%47633�%�"�3�%����,�#�(+'22�%)/�1���&1*%8��/��0����/��,ICU.��(+'*&
RESULTS ���
��$��%�Charlson������SOFA �LIP score #�&"� ����'���"� �%30%�ARDS%7%� ��'���"� �%30%�#�! �
RESULTS ����
"%!# $��25OHD���� ������������Ca�����������������
RESULTS PrimaryEndpoint
Vitamin D� 23.5% (125 of 531) VS Placebo�20.6% (109 of 528 ) (difference, 2.9 percentage points; 95% CI, −2.1 to 7.9; P = 0.26)
90�������������������������
� �"�
RESULTSSecondaryEndpoints'clinical(
90��%!��� ���#�&��!#����&�#����$�������#����
�����
RESULTSSecondaryEndpoints"clinical#
!90�� ��������������!28�������� ���������
�����
RESULTSSecondaryEndpoints�clinical�
�28�������������������90���� �����
�7����ARDS��� �����ARDS�������Vitamin D��4.1%�Placebo�4.5% ��������
������
RESULTSSecondaryEndpoints�physiological�
RESULTSSecondaryEndpoints2physiological3
17��/*.!���.$��. ��#-�0��()��+P/F�'AKI.$��+�%Cr�' ����.��'��".��'SOFA score. �
&���,(
RESULTSSecondaryEndpoints&physiological'
%3 "��25OHD���vitamin D����25OHD��#��!���75.9%�30(120 ng/ml"�����!��$����
%3 "��IL-6������ �
RESULTSSecondaryEndpoints%safety&
� �������"vitamin D�18��Placebo�19�
$14��#�!�Ca�$90��#�!���$90��#�!����!��
��� �
RESULTSSecondaryEndpointsBsubgroup)
=A:>7@�.25OHD��-�63&����-�,�/�234,#('�0'�����.9;8?A<��*�234'� ��vitamin D��
��*.���.��!-�%)� ��*/� 1%5vitamin D�.$���.�"��+,()"'�
��vitamin D����vitamin D���� �������
�5vitamin D����vitamin D��5<:>@=?;"���
&���5��'$&����,874ARDS2(0/��'6Placebo���5�+��4���9��,-1)/%.5�$� #�2��!4�� 63*0/%
DISCUSSION
•5*�.H��G54���Hvitamin DT����@QD8vitamin D��I3O;G� >R8���2NJDUEF;BA9
•!�#KAI/�&8%$&8�&EndpointsG6?C8,0�&G���IF=8L?SPlacebo-H�<�F+�@P:BA9
•"'�<) >RAAM8(�HW[YZWVXG4@Q�G817I��G��>RA9
DISCUSSION
• subgroup5�KP:9�Ovitamin D �O�1T&�O_][��Z�I�1Z�R:vitamin D4�O��Z CJ?G\`a^PMAHG;
•&N:<�3*O�1=L<$�#�EXWNARDSZ,*FJ?G�1=O!�'Bvitamin D��/KQFY9AHGDLP���K>V:�-Ovitamin DO�)6.�N�FJ?W;
• vitamin DO��7B�87L"+7K(MHJ?W�2�S0@UXGB:�%O�2�S>W;
DISCUSSION
VITdAL-ICU trial=ICU��FB��3��M��>75Z��E�-B,1'��2A8�Nvitamin D��CQ?USWYVXT �NO@99Z��E)�
�+/J�6+/JN9D
VIOLET trial=ICU��%�FB14�:�M��>ARDSP#�N<WUS�2[�5(B3&B ��LK\
A8�Nvitamin D��R��HG?LS/MS/MSI2" �R��@�!L�.B$�
0�*4�7; 0�*4�7;
LIMITATION
+'�A��C�&�B� K(�8>1I<E.FHPLRSUAWVK�I6@3?4:.#*)�K'�?A1� B�G;<�!�30I/
,OMSUQTN?vitamin DC��3A1@��7J.���K5A2=<� C��D%$8>1A1/
-vitamin D��� K��B��9I6@K� 8>1<<E.%���D"=>1A1/
�$ �
•�#TWSQXV�1vitamin DF&���G*NMD7?=81ICU�����FHY�9KF��B45FG1vitamin DF+�# B;@�DF7!�8�L2
•�)F."�E/<L,�8ARDSI��FURP��E/NL�0%O,�;@4L>:A3K1APACHE�ISAPS�DCF'�$D,�O;=�8-�AGD47B(6JML2
�����
•��8$&ICU��,�'-?0��4(23$�/.:&ICU4�#�'7��486+20%����+<:!� 5.38;; 96��,(=$����8�0.3!�1207+�,�>%
•����8FIHCD4�@?0,$AEGB7ICU5FIHCD7ICU48��7"�J!� K:�623)>5�*<?>%
B<�[34
• 0�]M1T5�2:�?GN<a`UL_J• �<34rVITdAL-ICU trials[;9VK_Amrein^[34J• H�vitamin D'�8[(�/Z.+b6SR34J
t34jgdpu��OI�!>I-�,�I�C1&I5�2:�?Gt!>ueqhkncImofqIhdhIldiIdfnhYX[30!>t%Eu2017�8$10"v2023�2$r0�]�F�st�@uICUZ ��72#E�I 48#E�[*�N=A\`_H�vitamin D'�r25OHD≦12ng/mls[���9t )uICU ��72#E�Zloading doseWPU54��[vitamin Db��JQ[�90"E4000�/"7�DV��J
Primary Endpoints'�&�28�[RW�"�"�(
Secondary Endpointso*@CICURW90�G\Y1�?W"�o*@CICUW%��?o5�+W2 1A�W qSOFAro90�+[RW*@CICUZW��@o<@�o90�+[RW�34I�6U��o)$W9
bdiekW7�X�,-S�JKX `OQG]MC;:�?I>FCgnjlgchI�JFCICU���HPvitamin DB�!�0V�8a.OQF_Cvitamin DW/���IE_CUTW=FIE^CjmifplSLQX�5,-V#ON�VUOQF_D
;6<6�$
•&��!81@vitamin D#���:"���8=)%��>RCT-?=��.(;34+2.)�':)���:negative study8�B32*
•���9 �-?)ICU���!80)vitamin DC��0)��04+2?#�1@6+,��: ���5: �/A7+*
LFMF&.
• �1,�I$'O3�/�*O����U 8E�"�U%A$'J���E<R:N?SG6;3��I(�U�=3���H9=Rvitamin D-�!�I$'J��KF:7F)8QSB4
• >IP7Gnegative study;NEJMH0CB>F+�H�;5RF�@3>>536�2�,CE6Bvitamin DI$'H�#;D6BP7H�TSB4
Top Related